96566-00-6

Basic information

• Product Name: 3,4-dihydro-7-(phenylmethoxy)-1-benzopyran-2-one
• Synonyms: 3,4-dihydro-7-(phenylmethoxy)-1-benzopyran-2-one
• CAS NO: 96566-00-6
• Molecular Weight: 254.285
• Mol File: 96566-00-6.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 3,4-dihydro-7-(phenylmethoxy)-1-benzopyran-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydro-7-(phenylmethoxy)-1-benzopyran-2-one(96566-00-6)
• EPA Substance Registry System: 3,4-dihydro-7-(phenylmethoxy)-1-benzopyran-2-one(96566-00-6)

Safety Data

• Hazardous Substances Data: 96566-00-6(Hazardous Substances Data)

Upstream product

• 5631-67-4 7-hydroxychroman-2-one 
• 100-39-0 benzyl bromide 
• 31005-04-6 7-(benzyloxy)-2H-chromen-2-one 
• 5631-68-5 3-(2,4-Dihydroxyphenyl)propionic Acid 
• 93-35-6 7-hydroxy-2H-chromen-2-one 
• 100-44-7 benzyl chloride 

Downstream Products

• 409359-07-5 3-(4-benzyloxy-2-hydroxyphenyl)propionamide 
• 403820-87-1 7-benzyloxy-3,3-dibromochromanone 
• 111598-60-8 7-Benzyloxy-2,2-dimethyl-chroman 

Relevant articles and documents

Design and synthesis of novel 3,4-dihydrocoumarins as potent and selective monoamine oxidase-B inhibitors with the neuroprotection against Parkinson's disease

The monoamine oxidase-B (MAO-B) inhibitors with neuroprotective effects are better for Parkinson's disease (PD) treatment, due to the complicated pathogenesis of PD. To develop new hMAO-B inhibitors with neuroprotection, a novel series of 3,4-dihydrocouma

Dihydrocoumarin derivatives as well as preparation method and application thereof

The invention relates to the medical field and discloses dihydrocoumarin derivatives which are compounds shown in formula I or pharmaceutically acceptable salts of the compounds in formula I. The compounds are prepared from substitute 7-hydroxyl dihydroco

PREVENTIVE OR THERAPEUTIC AGENT FOR KIDNEY DISEASE

The present invention relates to an agent for the prevention or treatment of a renal disease comprising as an active ingredient a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula: wherein R1 is a hydrogen atom or an optionally substituted alkyl group; R2 is a dialkylamino group, an alkyl group, a cycloalkyl group, an optionally substituted aryl group etc.; T is an oxygen atom, a sulfur atom etc.; Q is a hydrogen atom or an optionally substituted alkyl group; and Z is a hydrogen atom, a hydroxy group etc., or a pharmaceutically acceptable salt thereof which has an inhibitory effect on mesangial cell proliferation and a decreasing effect on protein excretion in urine, and are useful for preventing or treating of various renal diseases such as IgA nephropathy, diabetic nephropathy, nephritic syndrome and the like.